dr. reckamp on targeted therapy options for rare mutations in nsclc
Published 4 years ago • 90 plays • Length 1:11Download video MP4
Download video MP3
Similar videos
-
2:24
dr. reckamp on met-targeting strategies in nsclc
-
3:43
targeted therapy benefit for actionable mutations
-
1:13
dr. reckamp on pivotal data in metex14-altered nsclc
-
0:49
dr. reckamp on molecular testing in lung cancer
-
1:02
dr. reckamp on mk-2206 for the treatment of egfr wild-type nsclc
-
1:36
dr. reckamp on cabozantinib plus erlotinib for advanced egfr-mutant nsclc
-
5:50
targeted therapy in egfr exon 20-mutant non–small cell lung cancer
-
5:00
options for up-front therapy in egfr-mutant nsclc
-
3:30
understanding mutations and targeted therapy in lung cancer
-
6:44
treatment options for lung cancer mutations & contingencies
-
1:28
options for patients with lung cancer and genetic alterations
-
6:09
mutation testing for nsclc
-
7:22
testing for ntrk mutations in nsclc - 2022 program: targeted therapies forum
-
36:39
panel q&a session on acquired resistance with drs. reckamp & owonikoko
-
0:59
dr. karen reckamp evaluates the predictive efficacy of the veristrat in nsclc
-
5:51
karen reckamp, md, ms: results in phase ii advanced lung cancer trial
-
1:02:05
adjuvant egfr-targeted therapy as a game changer in multimodal nsclc management
-
28:28
patient selection, therapeutic sequencing, & treatment selection in egfr mutation-positive nsclc
-
34:23
management of non-small cell lung cancer (nsclc) with an egfr mutation — karen reckamp, md, ms